Demographics of the study population
| . | Controls . | TM patients . |
|---|---|---|
| Sample size | 17 | 131† |
| Age, y | 24.9 ± 1.3 | 21 ± 7.6 |
| Sex | 9 female, 7 male | 67 female, 64 male |
| Chelator | NA | 28 DFO; 81 DFX; 2 DFX + DFO; 2 DFP; 1 DFP + DFX; 5 DFP + DFO; 5 none; 7 unknown |
| HIC by MRI | 1.0 ± 0.1 | 12.3 ± 8.4† |
| Cardiac R2* | ND | 72.7 ± 52.9 |
| Pancreatic R2* | 20.1 ± 3.8 | 252.5 ± 224.4‡ |
| . | Controls . | TM patients . |
|---|---|---|
| Sample size | 17 | 131† |
| Age, y | 24.9 ± 1.3 | 21 ± 7.6 |
| Sex | 9 female, 7 male | 67 female, 64 male |
| Chelator | NA | 28 DFO; 81 DFX; 2 DFX + DFO; 2 DFP; 1 DFP + DFX; 5 DFP + DFO; 5 none; 7 unknown |
| HIC by MRI | 1.0 ± 0.1 | 12.3 ± 8.4† |
| Cardiac R2* | ND | 72.7 ± 52.9 |
| Pancreatic R2* | 20.1 ± 3.8 | 252.5 ± 224.4‡ |
Age, HIC, and R2* values are reported as the mean, ± SD.
TM indicates thalassemia major; HIC, hepatic iron concentration; DFO, deferoxamine; DFX, deferasirox; DFP, deferiprone; NA, not applicable; and ND, not done.
These 131 patients underwent a total of 260 examinations (2.0 ± 1.3 examinations per patient; range, 1-6 examinations).
P < .001 with respect to controls.